Arcus Biosciences' Series C Round

Arcus Biosciences raised a round of funding on November 13, 2017.

Arcus Biosciences is developing drug therapies for small molecules along the ATP-adenosine pathway; CD73, CD39 and the A2A receptor.…

Articles about Arcus Biosciences' Series C Round: